Post on 23-May-2018
-----BEGIN PRIVACY-ENHANCED MESSAGE-----Proc-Type: 2001,MIC-CLEAROriginator-Name: webmaster@www.sec.govOriginator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQABMIC-Info: RSA-MD5,RSA, L/KIwzq6x2QF+gwNshFlVvoRCg7wLHKfJ3hl1bYpKnCdVvslXJZmFZGenop0nQuC XyPfflLr0eRSnFro9+ZjvQ==
0000950134-06-006736.txt : 200604060000950134-06-006736.hdr.sgml : 2006040620060405182423ACCESSION NUMBER:0000950134-06-006736CONFORMED SUBMISSION TYPE:8-KPUBLIC DOCUMENT COUNT:29CONFORMED PERIOD OF REPORT:20060405ITEM INFORMATION:Regulation FD DisclosureITEM INFORMATION:Financial Statements and ExhibitsFILED AS OF DATE:20060406DATE AS OF CHANGE:20060405
FILER:
COMPANY DATA:COMPANY CONFORMED NAME:LIFELINE THERAPEUTICS, INC.CENTRAL INDEX KEY:0000849146STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:841097796STATE OF INCORPORATION:COFISCAL YEAR END:0630
FILING VALUES:FORM TYPE:8-KSEC ACT:1934 ActSEC FILE NUMBER:000-30489FILM NUMBER:06743347
BUSINESS ADDRESS:STREET 1:6400 SOUTH FIDDLERSTREET 2:SUITE 1750CITY:ENGLEWOODSTATE:COZIP:80111BUSINESS PHONE:720-488-1711
MAIL ADDRESS:STREET 1:6400 SOUTH FIDDLERSTREET 2:SUITE 1750CITY:ENGLEWOODSTATE:COZIP:80111
FORMER COMPANY:FORMER CONFORMED NAME:YAAK RIVER RESOURCES INCDATE OF NAME CHANGE:19920703
FORMER COMPANY:FORMER CONFORMED NAME:ANDRAPLEX CORPDATE OF NAME CHANGE:19920406
8-K1d34830e8vk.htmFORM 8-K
e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April5, 2006
Lifeline Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Colorado
000-30489
84-1097796
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6400 South Fiddlers Green Circle, Suite1970, Englewood, CO
80111
(Address of principal executive offices)(Zip Code)
Registrants telephone number, including area code: (720)488-1711
6400 South Fiddlers Green Circle, Suite1750, Englewood, CO
80111
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfythe filing obligation of the registrant under any of the following provisions (see GeneralInstruction A.2. below):
o Written communications pursuant to Rule425 under the Securities Act (17 CFR230.425)
o Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12)
o Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
ITEM 7.01 RegulationFD Disclosure
On March29, 2006, the Company filed on Form 8-K a RegulationFD Disclosure. The exhibitattached contained two pages of financial information. The graphical information on those pagesdid not display correctly, making the information difficult to read.
The pages, in a different format, are attached.
It remains the Companys policy that it will not provide guidance as to future performance of theCompany or of its operating results.
ITEM 9.01. Exhibits
99.1 Presentation dated March06
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalf by the undersigned thereunto dulyauthorized.
Date: April5, 2006
LIFELINE THERAPEUTICS, INC.
By:
/s/GeraldJ. Houston
Gerald J. Houston
Chief Financial Officer
2
Exhibit
Exhibit No. Description
99.1 Presentation dated March06
EX-99.12d34830exv99w1.htmPRESENTATION
exv99w1
Exhibit99.1
Dedicated to helping people reach their health and wellness goals
through
science-based solutions to oxidative stress
science-based solutions to oxidative stressscience-based solutions to oxidative stressscience-based solutions to oxidative stress
The issues addressed in this presentation may involveforward-looking statements which are subject to a numberof risks and uncertainties. Actual results may differmaterially. Please refer to our Annual Report and to ourother SEC filings for more information about risks anduncertainties that could cause actual results to differ.
uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.
We are:
A science-based health and nutrition company
Committed to developing innovative products
based on scientific evidence
Our product:
Patent-pending Protandim(r) strengthens natural
antioxidant defenses to reduce the cell damage
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
known as oxidative stress
Public in October 2004, LFLT.OB
Protandim(r) shipment begins March 2005
Protandim(r) featured on ABC Primetime Live June 2005
Human clinical trial study published January 2006
Additional product expansion opportunities
Leading antioxidant research scientists
Internationally renowned scientific advisors
Experienced management team
www.protandim.com
www.lifelinetherapeutics.com
Corporate Overview
Estimated $3.6 billion underserved market
Science-based
Unique position in the health & wellness supplementmarket sector
Market moving to evidence-based
Clinically supported
Additional product expansion opportunities
The Opportunity
U. S. Market Opportunity -- 2006 estimate
Growing at 10% annually
Source: Data Monitor November 2004
No Clinical Evidence
Clinical Evidence
$3.6 Billion segment
$30 Billion Market
Oxidative stress is associated with over 200 diseases, as presentedin over a thousand peer-reviewed, published, scientific papers
Examples of areas where oxidative stress appears to play a role,based on these papers, include:
Heart disease
Diabetes
Cancer
The Problem
Oxidative stress (cell damage) occurs when oxidative balance isupset by increased production of oxidants, or by decreasedavailability of antioxidants
Humans produce three antioxidant enzymes naturally: superoxidedismutase (SOD), catalase (CAT), and glutathione peroxidase
Humans produce about 0.3 mole of superoxide (free radicals) daily
As people age, the body's natural production of SOD and CATenzymes cannot keep up with increasing levels of free radicals
The Problem
Overview of Oxidative Stress
Consumable antioxidants (e.g., vitamins C and E) neutralizeoxidants on a one-to-one relationship
One gram of vitamin C per day can neutralize about 0.01 moleof superoxide per day
An amount only 1/30th of the body's daily production
This assumes full absorption and complete reaction prior toexcretion
Yesterday's Solution
Protandim(r) - patent-pending formula
Specifically formulated to strengthen the body's natural defensesagainst oxidative stress
Delivers powerful antioxidant benefits in a whole new way
Activates two key antioxidant enzymes - SOD and CAT - the body'sown defense system against free radicals
Delivers benefits on a one-to-a-million relationship
Our Solution
The Scientific Evidence
Free Radical Biology & Medicine (Jan. 15, 2006)
TBARS are a key measure of oxidative stress
TBARS are considered "the canary in the coal mine"
After 30 days, 40% average reduction of TBARS
After 120 days, increase in average antioxidant enzyme levels
SOD +30%
CAT +54%
Protandim(r) Study Results
Causing modest induction of SOD and CAT to decrease
oxidative stress and lipid peroxidation in vivo
may be a much more effective approach
than conventional antioxidant supplements.
Protandim(r) Study Conclusions
Increases the body's natural defense against oxidative stress by morethan 30%
Eliminates age related increase in oxidative stress
Fights cellular aging from the inside out
One caplet daily produces results within 30 days
One caplet daily to maintain results
Protandim(r) is the only product that has been scientifically shown toelevate the levels of the crucial antioxidant enzymes SOD (by 30%)and CAT (by 54%) in a human clinical trial (published, peer-reviewed)
Protandim(r)
Science-based
Market moving to evidence-based
Clinically supported
Premium product
Science allows for premium pricing
Protandim(r) Positioning
Aggressively working to obtain and protect
Covers any combination of the identified botanical extracts
Covers end outcome: induction of SOD and CAT and reduction oflipid peroxides
Protandim(r) Patent-Pending
Produce clinically tested products
Protandim(r) product line expansion
New products
Based on science
Science allows premium pricing
"Partnership in Wellness" marketing campaign in development
Partnering with leading companies to spread health and wellness message
"Women's Initiative"
Clinical lab testing for TBARS
Corporate Strategy
eCommerce
Protandim(r) $49.95 retail
3-day DSO
Autoship repeat customers
Retail
GNC
Pursuing other potential partners
Chain drug stores
Health food stores
Science allows partners to charge a premium
Licensing + OEM + Partners
Domestic and international
Corporate Strategy
Distribution Model
Featured on ABC's Primetime Live June 2005
Consumer advertising
Print and eCommerce - example targets include
Wall Street Journal USA Today Prevention
Newsweek New York Times Yoga Journal
L. A. Times Delicious Living I Village
Chicago Sun Times Women's Health Alternative Medicine
Dallas Morning News Palm Beach Post Men's Fitness
Chicago Tribune Newsday Men's Health
Minneapolis Star Tribune Denver Post Advocate Houston Chronicle Seattle Times San Francisco Chronicle
Better Homes and Gardens AARP More
Ladies' Home Journal Fitness Rocky Mountain News Value Click Network
Atlanta Journal Constitution
San Diego - North County Times
Corporate Strategy
Product Promotions
Consumer advertising
Radio
National, regional
Premiere Radio Networks
Westwood One Networks
TV
Direct sales
Direct response television
Scandown supported
Co-op supported
Off-shelf display solutions
Spokesperson(s)
Co-branding promotion
Corporate Strategy
Product Promotions
Virtual company - low overhead
Most costs variable
eCommerce model provides strong cash flow
Deferred revenue model approaching $1 million
Exceptional Gross Margin
On-demand production
Financial Model
Financial Summary
June30 Fiscal Year End
Q4 FY 2005 Q1 FY 2006 Q2 FY 2006
$ % $ % % Ch $ % % Ch
Revenue:
Direct Sales 2,393.8 102.8 % 3,011.2 101.6 % 25.8 % 1,757.3 102.7 % -41.6 %
Sls Discounts (124.5 ) -5.3 % (245.3 ) -8.3 % 97.1 % (155.9 ) -9.1 % -36.4 %
Sls Return allowance (124.1 ) -5.3 % (40.0 ) -1.3 % -67.8 % (35.2 ) -2.1 % -12.0 %
Billed to customers 182.6 7.8 % 239.0 8.1 % 30.9 % 145.6 8.5 % -39.1 %
Other 0.0 % (0.2 ) 0.0 % 0.0 % -100.0 %
Net Revenue 2,327.9 100.0 % 2,964.6 100.0 % 27.4 % 1,711.8 100.0 % -42.3 %
COGS:
Direct 221.2 9.5 % 217.1 7.3 % -1.8 % 137.2 8.0 % -36.8 %
Other 162.4 7.0 % 379.5 12.8 % 133.7 % 225.8 13.2 % -40.5 %
Total 383.5 16.5 % 596.8 20.1 % 55.6 % 363.0 21.2 % -39.2 %
Gross Margin:
Direct 2,106.7 90.5 % 2,747.5 92.7 % 30.4 % 1,574.6 92.0 % -42.7 %
Other (162.4 ) -7.0 % (379.5 ) -12.8 % 133.7 % (225.8 ) -13.2 % -40.5 %
Total Gross Margin 1,944.3 83.5 % 2,368.0 79.9 % 21.8 % 1,348.8 78.8 % -43.0 %
Operating Expense:
Mktg & Cust Spt 923.8 39.7 % 1,144.5 38.6 % 23.9 % 829.9 48.5 % -27.5 %
G & A 1,125.3 48.3 % 1,065.4 35.9 % -5.3 % 1,041.2 60.8 % -2.3 %
R & D 5.1 0.2 % 0.0 % -100.0 % 0.0 %
Dprn & Amor 101.6 4.4 % 86.4 2.9 % -15.0 % 83.4 4.9 % -3.5 %
Total Operating Expense 2,155.8 92.6 % 2,296.3 77.5 % 6.5 % 1,954.5 114.2 % -14.9 %
Operating Income: (211.5 ) -9.1 % 71.8 2.4 % -133.9 % (605.7 ) -35.4 % -943.9 %
Other I & E (2,595.8 ) -111.5 % 8.5 0.3 % -100.3 % 34.8 2.0 % 307.3 %
Net Income (Loss) (2,807.3 ) -120.6 % 80.3 2.7 % -102.9 % (571.0 ) -33.4 % -810.9 %
NOTES:
Deferred Revenue 483.8 293.9 -39.3 %
CASH 3,385.2 4,762.3 4,871.9
Lifeline Therapeutics, Inc. LFLT.OB
March06 22
Balance Sheet
December 31, 2005 June 30, 2005
ASSETS
Current Assets
Cash and cash equivalents $ 4,871,904 $ 3,385,205
Accounts receivable, (net) 528,106 1,020,131
Inventory 139,689 219,644
Deposit with manufacturer 642,693 991,560
Prepaid expenses 129,437 415,806
Total current assets 6,311,829 6,032,346
Property and Equipment, net 257,717 200,944
Intangible Assets, net 5,472,020 5,578,830
Deposits 296,144 31,192
TOTAL ASSETS $ 12,337,710 $ 11,843,312
LIABILITIES AND STOCKHOLDERS EQUITY
Current Liabilities
Accounts payable $ 570,022 $ 657,528
Accrued expenses 445,510 207,672
Deferred revenue 777,750
Capital lease-current portion 1,844
Total Current Liabilities 1,795,126 865,200
Long-Term Liabilities
Capital lease-long term portion 4,176
Stockholders Equity
Common Stock, SeriesA -par value $.001, 250,000,000shares authorized, 22,117,992 issued and outstanding 22,118 22,118
Additional paid-in capital 17,282,858 17,231,832
Accumulated (deficit) (6,766,568 ) (6,275,838 )
Total stockholders equity 10,538,408 10,978,112
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY $ 12,337,710 $ 11,843,312
Lifeline Therapeutics, Inc. LFLT.OB
March06 23
Joe M. McCord, Ph.D.
Co-discoverer of SOD in 1969
Honorary President of the International Society of Antioxidants
in Nutrition and Health (ISANH)
Recipient of the prestigious Elliott Cresson Medal
of the Franklin Institute
Professor of Medicine at University of Colorado at Denver and
Health Sciences Center (UCDHSC)
Director of Science, Lifeline Therapeutics
Board of Directors, Lifeline Therapeutics
Sally K. Nelson, Ph.D.
Assoc. Clinical Professor of Medicine, UCDHSC
Lead researcher on Protandim(r) study
Science Coordinator, Lifeline Therapeutics
The Scientists
Larry Gold, PhD
Founder, CEO, Chairman of the Board, and Chief Science Officer of SomaLogic, a leadingclinical proteomics company
Founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstarmerged with Gilead Sciences, Inc.
Founded Synergen, Inc., a biotechnology company acquired by Amgen, Inc.
Professor, University of Colorado (CU) since 1970, where he served as Chairman ofMolecular, Cellular and Developmental Biology Department from 1988 to 1992
Awarded the CU Distinguished Lectureship Award, the National Institutes of Health MeritAward, the Career development Award, and the Chiron Prize for Biotechnology
Sean O'Connell, PhD
Chief Medical Officer for Cascade Medical Enterprises, LLC.
Assistant Professor, Department of Surgery, Division of Vascular Surgery at EnglewoodHospital and Medical Center, a Mount Sinai School of Medicine Affiliated Hospital inEnglewood, New Jersey
Medical Marketing Director for Novartis Pharmaceuticals Corporation, East Hanover, NewJersey
Medical Director for Sandoz Pharmaceuticals
The Scientific Advisory Board
Stephen K. Onody, CEO
28 years of experience in healthcare companies
Chairman and CEO, Colorado MEDTech, Inc.
(NASDAQ: CMED)
Vital Signs, Microphage, Boston Scientific
Recipient of entrepreneurial and leadership awards
Gerald J. Houston, CFO
Founder and CFO, OpVista, Inc.
ROLM, IBM, Measurex, KPMG Strategic Services
The Management
Javier Baz, Chairman Private Investor, former investment banker
Dr. James Crapo Former Chairman of Medicine,
National Jewish Medical and Research Center
James J. Krejci Exec. Director, Epilepsy Foundation of Colorado
Bill Lister Ret. Senior VP and General Manager
Patient Care, Roche Diagnostics Corporation
Dr. Joe McCord Director of Science, Lifeline
Steven K. Onody CEO, Lifeline
H. Leigh Severance President, Severance Capital Management
John B. Van Heuvelen Ret. President and COO, Morgan Stanley
Trust Company
The Board of Directors
The Future
Grow Protandim(r):
eCommerce + Retail
Licensing + OEM
International Distribution
"Partnership in Wellness"
Additional Products:
Science-based
GRAPHIC3d34830d34830z0001.gifGRAPHIC
begin 644 d34830d34830z0001.gifM1TE&.#=AT`(!X2IXP\`O_>FQJUO0]%9))?ISYTH$$'-J0B+@#MHYU]U/@_5C7N?M-M[G(+_-P`70>[Q2F0=;%CG>8RET#$I)$XR8`MY8A:"","7!``C0`3E#(``@H_T."#*Q)MC'JF\YT'_=P?*2#PJ,*YW16OF`(C(M2>8/^V?VT5(7DOM&='#8G1FH93LG(27KN,I^6R&6G!G.W8?:F#S'\%U,;#9.,*USI6?'#ZD6?EHM5CKVV;G`/J_B["AIX4X;H08D*Y\G#5RP,ERY!=?M/8>=\4GSF:)YK*MY/_VXM*^WIL?!*T[D@1('NG"7_4;Q?G?CMPL7K'Q_>:X$3\L[\#F#9H0OIXIZUQ\'E8[,_//V)H]V@O=9XVY&;Z#TK>\-KMU7;7&_I\D90$[``E`P%J[!'R-(!K^)TZR)Q6HL2U!L6`:N$LZIU6BME3+/T&U>AT?8U3_E55CX4T$+%(,`)(,55`(:4/\".KB#):`=/=B#)@"$V5$"M,!"$/J@=1VB$/\B#^*.#-GA7-!A!,.B";>16'5\5SA^>B9/D#1PUM9CM?C5)Z,5]*U9DH?1">L(:5O,:V&$#3#001D)@`@5%EKU)@B)&3?(F7AH9`1=@&;.XC$9HK8;EDT9J8QKD.>BF-5X2*Z]A`B^W#1%9J(1`MHZTU"+U9%HI05)-)")7R%7"QH8$:%.W*>#5ZJB?#MYL"&)4B"4JRIR&(M&>YM"$6U_PCYL;>^X`-2*WUD1+6L&[B45SY/9+10RPANJ;)Z`Q1RR@AN)H"6(@E=M9A:=4KQ`(:."`!S3X570@?V1Y*O3N'8",$QZ4`^7!3=^@@$4^%FOD@5EFKG56+1:Z9(HXP(9UH0&YPU04>-WGM]6",,LYTMQ$W':?1*"3XPMXE5S\T(9)#]=79)5\EH9V%4895`UD9DS;):!FGA,I\P(`WCM408Q^)"D,OG])F288DH#1`\:0%``,191D%X))MSG23P8CDEGG#J7M?*+0[-QP""[Q4:X?*XD4XZJOYG(+8,*;C8,OLP\GA(`\,+K@\B&(K2P:%68@RJXJ)#UPUM.4T%:B.TN10:_1>,N53`!%L")'8$$P,37`EC[L'%*H36K*M]8HK=LZ0I$S=Z6"^2Q*SXJ,LFC]'A*J?@`!]_0121]04(`M*K($G/I@/;12CP\&L;=HQM4(-JQ4K9]#[J11*-!4#FQD`GRI%RX@D"*/0P)T.B=7EE7HYV0TR,1AR3-V^R&TKB12*H&KS66+F*I,3/T*!Q*\_#,5WM32-MQHMF&W`M1S1R(T8.UR,1GM1^MD)N2Y=+M)$Z2RV12>XTF>ZY`/6EF>Z1F=Z*F>[6F=VNF>\2F?\TF?M]NTQ?N?HK"M&U"LJNJOB^NM=FJD^P`$SINXB&H!V)N]M3GNVNHJKGJH4F!NHQFJO;VL!;.NW:%JW6PJRGR`$,L`!^2JI44NX?B&X`=NAMV:J[A"K!84NH;/NR)4NF4,T00_W*VKVLSDNII$FZ?0&^6(VF`Y[#=_T7TM3-)U7^U'M2IJ5LO0/V?@TW?8/->*^OZ'-(K^[7%FNRKG*96C.%H"L)#D/%^*P/WGK@L#_%'&^GDM$8WJ9/#>H`E:8$W[^3G-3$?+/R.SL1!6-?+:[RM[BDLD+@7T")!?`']JKCG'JT7OJQTZKRH+`)\#@HO?]@L;PV6[]#@$`R&7YW@7F6\\394;BJ[K"F2@^KD022,;BHE.PHIZN5BZ@KB/>Y[?MY+-.PK$OB[OW![H7N&&QN3LNFZ%8V[*B5ZN16YXUM[J.=H'8ZK64RY^362D#M8D[PZ*YF-KXVNK7'RPK@=*E>68>I0!$5LZ_5BVL&*[RS5KM^EZ-J(;X-P[9`MZZ8.UZ=FFY/MJT&%VJ8;^I4,1[>/HC"B>YG@.L"?!TYG,$?O'M!)L$'M6[@F]@_NG/\MW>"RPM\LXG>6L&:A-Z%N)M[XBU8FO*4NO!E[B^KIRJ`^QP3GL*3MNI%X>NQ[QKZ[NNJOJPYQG.5GNH;LI]MP'MQ[CK.]V/%6INI^[F>^NK_O9;`#>6LEV=5YYQAF?G7R5&J08,36,:S.,&]9-JH9UA](5]O+2CS$P09TJ8(_G-=+D#@Q#I6PM.XWK7;%_1XMD,0W+10`9IK&.=PRTC>-?5KBZI\2:XRUZ;TK;.)Q$\#6#?M+D\I$,G@**1CDZ!41@8UK`LGLT$@\>4KPRM@]CYU,F]IXU-3I?CNKTE_VUHBWUKC7/;V#R.'$Q3G,)"JKAN0ICN/PHN;00#MN1O$-F(AM\MD`RUXXHR,]SV0^^?=_MK2^"J"$4C.X;XY5>"3_M]>8;&C33ALD-C622BPL5I1X&J,/\K(-W-L;5+&X6_0K+02E=A%M'J:T:?7UW3(&GPCNL:;1_D`UP^*G!/5M=ZL\J5HZ>O$=9Z^\(2GS)4>5-J;SM?&9[W/%S8*[I'-XXZ#VQ:-8KF_'^F:J3$#,.Q24=]S*)ZR=V,X*AE503$"()RWM5W!H(!"7=9ZE:GPX6+W86^A'BX?&"QC$8,_0>3WX8S21B]YG3YQF+/&89DAE(,`&@Z!V_TZ"R(MJ)B9M>&X/])!;Z!7.AF($&'T5F70CMN7"\]T'GUXHI%U*Q$&SGF)2!MF''QXZM!T(.4T=>DGLAA&9'_:M,V#7E6'PMG,8AW40V&Q2=VM"0&D'^6,#='8(1XDFP7$!]'FW&(7,AVM".(FVM9FF\M'QA"6ATN9^)%SB(,@A6PCMMH.Z1WF[^#^=>);:=Y`XQQXTH38V!0*J;QZAE03H*;_J9'Y:;UBD7:8H$8UW/5$FM8**9@089I"\97KB7#`>*C!=Y8O)IA]@TA55S,NH3+3?SFI7X[@M&>D`-+8A7>"9>02B9H1F(/&W,(`I2E`71YI(,.:"-!+VH_U@$++2%`M?)0B0L0(C+>,D$*DC#@@VPKMX[BAXY^#8R\OR@TA\[5U-*Y)ETJN!F`CQ(^O]U(5ZESM*58B)X(0@5^_(5_]M=9T,A7]WB$3%XFMMY6*Q]H5TFSH@EK%5JU.%LK=:HA18!"@!XQ?2.;@)$2:3MPCZ2JT$I$?^NBVNU=O%&>G$PVK0HU3*FSD.OLBN]Z"`K&'$6=EM'9N(W!S,IM@@M`2E18EY"7^MHI^6$AE((V7)&U!A,AC+08@`$Y;GL:('*G-W:W"BOM0H08(@I6`4PI!72TZ42L";A58C9OJ`:1-BM%"G%C*8=,HW9ZM^M5-.MA_S/)117I[Q_.EW5=N+GN$'O%[!\.E1(05@@/>RR"`$,5B[RM!GUL(2,@);&O;!OEB\YW:EI,\17-GSM^LLW$ZC8XJW_R1'ZXB"-4Q`7\SP=3+C/Q=NKDX%A=-:J-L[:-6*UGS7/W\U!L>F%#B;MN+"Q9MR9?TFI`98=Y:P&]N;?3G@$VTLI$+CL''%E!T_R)X[QMD0?_&YT_&3/8>))2A:`\\I,;[^N^;>1%+8QK"?/IX_X%7,!0#P%OAG6RR`4O[I02[LD,*OWE9/ER),*MBM)OW8.;11$]T+(;'Q(%*ZO`DKD.'B#H"9"O`#JS-3H0M+!K>2KK>!\^5F*;5L?=5P^IEY-M_D+E=6`]YF`2/EYT)>8[BM_*C%V8G=/K1*+Y>+Q%=RG0UF4Q=SNQ605EG5Z,G5A:)>FO%34T-FC"MY=AV!D`5.__B1\[H%:[FZ%5=#NWF,#3BAV[C+99#4U;HB,5IW_UI"559$'9GME%0Z`P;:^QU6`69A:TYFH\9HJ:JKK*VNK["QLK.TM;:WMN+FZN[R]OK_`P/($.*'$FRI,F3*%.J7,FRIJR>5J!F+I(H)OAHIF@UXNF&%R?O*&MJI84.XC_'W*3VX&IBGE!676;#-L![@&7^.::.SZ"XXU#GKCHE#LN0G2'Y:BQ=%!IHYF@QFB4H)RED(I2MP,DHV5#%KKX`GZK,`RXV=)P\C36\F0DGCG84PZ(XP8'-T$@#^1^,M^*:R&$*H&;U1WC"B:AF3)6NL;:#\'V@F!M5@(YNV&SD@W%$9MJ2&!I=R).3F-!%EMK7ET3V4?+Z69B\P:F$$''^"%2&54UMNR-I$/KO2()1-09T$G&0P5E@A:P^'MR$8Q&8$Z9=G_TBTF;0VR9MH&,/I:F6STM:O7X?D=@@S&'AJ&YC]H3VMA;6H&;_YRBD],E!7=^\0]Y->)#,_O#?;KWM-HW$H((PW(7!W*Y=SKH/*ZIG;36:@G#VTF(%VK7%>J"+Q3'+QU,I1UB!`D87_FX4U"5V:YIVS7-GAV(8=FL7(\`K4S1D+9%R46R!]N,R@9NRK7!M"8]R13'QC94E5*U@+3C$V]9*AI^D3V9J6)]V3FS2%+3L'FM%6#'T;&GH[-7YMC0K]'#Z!96"1V7Q5K85(W6B&FR96AC-=G'?J//*9?G\*'2E!'7*."$YEKR/IM7,.-'.&`??&$#>-1EY6(5E,5G]6D,9]?Z/3,!EJCK$7X7D'460!_D/ND825I6%:M^45,D[$7-2SF.=#9&$(R>J6%D22FJ:UMHOL)^5,N+L8I0?.";V8+2KY,@="FT\\UM2)JB,;1`=%1NWXQ`;59`G?W]SP5C,YT,DYJ5PW#=H&;K1L1`#=Q3(2\M-/M>=7C%B%"[3D2GG4CIBZ5JTFW="6:`?PY>,;BZ,;5U%)N@R%C./F49'5VOMZEMP$PX0['@[XDV7NPV3NQR/-B3NEL+GC=B4YHI$)V_8M2YO37'S&>79H%PUM-YJ%CGEA)5G)32[GR"$6+7R;^Q)*RM&QXD+"0]*9NQHCA)(\0QL,(Y,2\AH[M9$)TY%&T`O4D-"Q$+#HRDOOWZJQ#'!!4/CM'^M,.TO9&+R8QU]X)SPC-FBN$^/'O,*,C!)TMTF/E6BE&@:!R%[%2-`J,IV3B^'M5'0((!O!HPYEXA)3D#MM*>Y2XHCRHH]=^.A1(]%&XHNO#Y>S#L_E8!/GOT/IM6)4.48@*%()DM[70ST:-"V/*9>)@M';-I$;R&1#]*R6D]A.IAU_B`"/2HMQ2WE`$J&P.60T!QE;ZBC8N74$KUU,>$5>'G?3V`FC#N5RQ_L89OU\*"CM%B'M)HE(Q7O,8@K&20U/-2DA`RNG510Y):5HB8'"VQ(W@*DH))P%+-`B3=?0U2N`%(93M=KA22RBV-\Y!YB7B-(=/GB"27YPP03J;A?BJ4ZC6K,RT5Y.(E$#S.;1YO&[F2PJZ(QM!5M1(2B3%K3'O9'#VD4M4((2C`&X5^[XE(KV":J!M4:]U@!9=2VLB#UM8EDX+6V-2?$Z8C@7AQG![4B#?5C4JVF4R#WA>VAK%\3AJ5.3F:M:4RS(%)'J)S;5>A098!APD-43AFJNYZX"G..76$AX)1![!42:OLG!Y$1FQXAM'Q\7FI_T3%9-]9`R_L`4H!'\VGR;F_'Y[=IB"46(-3N!$Z>*ST]XB605_)L4MTO_=+1+5;N[37T8VL"ZA8FC'./EF&BI9^BR4&(VBHDB-"M2*FB,GPT8T?L`37M6ODZ:%H?6CTCR%K+7P$,M`-1.RW8_U3,EMBCP`!JA(KKFE*+G2.J#9H!#!%=MNQ(Z,UV\6&MIOO.C%M:S%!\RN[`($7&)UYFRSC+)U_K`B2")5VG%EI$3ET41M(N$93YFZ`H'+*#IL(A?=)H>H0IKR.S.B*>E(AI^U*=JM.*@QVXYI/+Q!L,QR*3*Y`:SB#\?0R+4QF7RINN11@D:2!37"'*`IR[`]C0M9MDEY[--T11FI(4@193&8=3$;@-E&BE/*Z6=30G$DZ(?1$U[0T5ZVB1*REQ>-(M3#-1$B4R.?]T4K'8W-5I]=9)(="6M7,M^T)1>3`^/7!+]LE=4SV``R74\S%`EU_52B=PBI8%6!$\$UWY-&R1YVX^X7FEN/S4[PT%[?+M-%B=HSK;47Q@5&R#7V5(=DF&=%%X178XCE([3D>29CMM1E1"56*23.6I:ATA]F:YD=&A6=F"'-G"B.J=E3D^YKE92MUY4MG8SU63877CFL>P536*Q!/AJ2FQ0T2&YK[M+:>1E49(G5H^>A:,SA_!PY"J[$CSHK3AJ`XLM#ZHC1+@.@5=).`^)4Z)RC;%I%,C687"K$O,-Z.J(YL):W@"D=5\ES+F.KY=)MX"1]B'Y[1EX55)K70%B'T9EB9`?0(0&U590-QJ'-J1WA3&L$.*KLR$)8[$H?M)!ZRE2SY5*U!%?)7F,3HG.H0:(B?D,@_:D0%M5LF,&:^$B*SX]K"GM6%(H9BC65`&BI_5;5P0D5E18D*1D@0*4W"8V]MJXQQ1MU"(BBU%4>?91MH"YPHY\$)PV-O]VN\5UKRKB745[Q$$WTQUUVE)RLM9-$?T7S"XCQA$D9J8F;-Y$(G*`9"8*6M@A7YQC"6U";C./!%#DS'BQCQN1H.M274#929%YD:=$#W!12H!FDJB],%)FKPUY$).9++'^VS%'0%:+U0:14U)MG=>77USM81C4"V(,$@])Y*Z4,;.0%U#5OQW.A1.>B>4VGM8(_HG0/5&J$@++M\S^D7...WULCW!?31_Q@6'J:F%((LMXQY+1!!L$5U%8^?D%^OXKDYH8O*LF\3L7KK08EWI7.5FZABXFL2"5>=H[8$UU8O'T=RI5XVOO9AA*S.6]P:S,RMBT%RZ,3]7'(/3K3Y4&*RP]V`PUYWR/]YC(+MLYI!W'#6=\*S[671>31[M[^XS$Q\16?P=L8WG`+;S-B0+Z)P%^0PV;$0[*%\F:5MLOO:)!Z5CW@PI,JM;^O2%)S:7PGG%`$FU^P2QH,98-?7=/FB?_GU*T-\*8`0DURG((B*_MH+-4/QMMZ$TJ^L@E]/%:V033'=HP//"")2[;7M.1&-@MB4N2)6]@IDAXQX+RTI,XEG#3X8:\)VY]=SSUV&/YZ("25V(EIIZT5X_ZZ`8UMJD@&]Q0(QDC]*%[#4FZK-Y`^J?M\1DXZ;F>,^"JX`EZY2F41N>"M&>!,_2FB.&@3@2&Q"6,BME2S#EDZOE[F97#D[,M,\;R@N;B8K7'J@H)>%"0$6F;,XQO9MM9>"&C8!8%[IJG+&$%PJF"VF9*.IBQ]=?E9"7Z!_8:N/K041U%9);`M41ED[8DG`PF&NC7M2_:5NZ;2-+Z;(#IA/WC_"AGX]`PM.VD/Q%GPQ:$FL1ZNB"6RTHIJ0'^`*3:0M,BI5"R+;040*RA#FI:!".U"WZL3)C$9W8`;")48[:Q(;ZUJ\?FF8=MM49*)`.MJD?G^9U$ZC\BYYIX%V1[>:R5!\`-.J9Z-Y$!)?\M9@X);&+`^*+;R&PF=P_$6)#8%I':IKM3N(UFUU!J>&FJ\%P_EW*!!@(W*DXPM!E8>O2)K0643,@RNU#DN(C8AV6@QJM0UMTQF=E"=^57(STH/T1.MU'?__JB]+095W8I#@-55W^#%+_!6I\1ST;SZME_IL(0X[W]@%G_.HW^VO[VK4`23JX#_$#-E1A"T;#>REAM-K-$116:#[2;&'M6J#B;C38M]L)MM^/6BXR[O[^NNDN"F^$,V[M"],88Z0J!G$G+]JL,Z4^^LY@8@8FH.##*2/SJ6M'3^!)40S`"EOK)7"DR>E"MC%CLZ)=!T+RP%TC8R^T15]"4`S=6ROKD.3`^$F'31TZLVD@+TNRNF*2J\MV/Y4"*^AMXS,J*&TO5X>\?HD_99C15T03)HV.,G;$*:J=8J0:CEP.B-K&_,LT7`CZY@HQF,B:J,QAE$.VG>92Q!\XYF7,:IQ,J"7M(6JA*L"EJA+.I`P1=\L!.8)J%6'72>2/HXY$0;[KD.ZSADF8B+M21[H'D\A+J)5D@';WD98M\PX"[)G+59@MB=EE`;:RAY+"U>`ZZW[_*4[4'LNZ^[:)TX48G783`HA+&8(9;=QKK?N71R/FMS[@96:\S%1'0B.2)V+IE(`0E6+@?YDE*=V66RX;_!^EI?/,=?FW@JK/]DZ'@M]LE+E,H/33VUE5Z8G#QB*?B4J#G7^3@33T8WB3S:P`"WR'D=26^:\3U4(]$DM#_W+\B!Z]"`15V';0#Q'S`.ET@OIWLEX[[N!S0B2V-FXI?`KCWTM"0!SJJ9H0NO\;YQHR_)."#Z,[A'PP!2@2J;05EF(2`"Q!UZ!/MN*_G&M;,!`1AFJ@@N)+OZ4@W4$8HOD1Y%V;,Q(BI9XHY84!YODS,P*YO]([PMS+]=FMR?]J,JM#5N\K_,/6XB>SZ("7]$RPZHC('$,BKL^@/,3KX`X'3B$ZH`/$/&0,M#P04E*J'/@(+E@SO5,?E&`=]L"@K'N$S#N>VB,1IR`_,_*9K4'%_0%!V:B6>M@"P(E>04'2'2L##M3*694I%M#J^"$+`(NP4!QP(:]&G>S%#!C*ZIY.V:ZJ^SM3C!S%LC,.(7R;G!$Z`_M/JEMB*AB0BBHT-`+"\'E]D$?X*:&JM"&+LD>;/`JM6N$@LDV,H&VV[">JZ&*VW`&;IJ\'"R$9*4);`B+>TFN+,FBO>UI"'0/,Y%-WB+#+").X!#@KKB7'(Q1B2DABJ'XY92'.Q!ME"!J(D/")G(C3]+G^$0#`-4+^\X,?4P/]1R.?$QA>-HI1SJQ:>RJ:P(#GU9#M:U`F+S+GQOH$3`X/#:D&\5JP18J1]\9C>'[N"+2F;4:L%V@)-*3*8^3J,42NM(XTFXQ1R,FO+K&@@)L3A^M2Z."NZ9.^$]*6[WXVQ:O`K7DRIEHXMLB_0[_^?,DN-1I`ZX86TFHKLQS_F(W-J8>AK-&RVP21\K&*M#*1$$*M\&N9`L,;JB=8]],.'8K51$=3M]`V/>F98L(&)A$,B2V(56]G6M1XKF9(W0+Z(D$GN[E0Y*/PVDECW]W]_R)_TR;,4QPIKS$\D#+#D:DF,M\PL%1UJ8,_^MF.X]SJYKU&AT\I0F`I`CP9`3E9`4FJW)NJ!/[_`$WP]"JW'WMVBJJ-+2?'B\44M#YGE*=RN)119%*OTUH:L2*4'6,GS47>./@&.D=TU4)?78]MR+:C5((F$E5*4>9F'EA1+VD--Y4+TS+'G0M'T%M2^DR\\$."W6;GM;,0:#W6]4M((+)Y5`!_Z@7':\/][/W0>VCM%^/JU:YZ91)7+4=$>U-7@L/N78\S8C-+U?=E);M@;#N+^A&M\-3M&%>JS&7P"N;K_\(AK0M>G.>Q2O"'$^?8HM^;]H];6M]\^;?K=BJ-W.P-$US!A+MMKR0_6.W/HF;@TS24'')@PT.T:408M%]8X:HJ((Y7E6["ZA@#EQM+=(4Y:^K6"QO]:JWR$[53@)+5N0O132J):O+"JU/BUYC&(,O$-%S**BVZ5E?3@Q^)MZR#*77(UM:O%;H\IB"L>`[0*Y$PV_PVA-/I\-`%M5C%\"K5MNK2U96W-RTE9?I!:^QL"77Y&!"P^RYFK]GCPFNF4'!Y>1PXSF*!7_M6:M7MYY@#CM-CZ/@@W[2=?(5CW;\7NT"NA5+S]2YT#-*SO:^%9R@C.9[/,PWMU_\555&?322"!$%.:L/KFV=E(G']P?553EVG9QW/W+99:0LK!,\2`>A'EV58MQKP7(E-KWW6>"1Q%P>36%;?@YA^_4H]_=Y"W#E5^>J?0J8>8:TU40J\=L,\HFZ.\'"GH>LJO8B[.M:JM.^9\/K#YM6ZYGNT^6W"CRZK3X*!EVJ,4?R[>>`T:(.4O_6$/(B>A,:4.O$8M(K&A/?@8>BA*4'&VP;#3M&*F8(,&&L2PPE$&7-R42:-#SE*XP0L-PLM/MF(1&KSLS@X@E]+M$8HGC28-^MUFL)+HM**W(%#SO;79I(CCLRIYDB4W;#=VTQ6?W&@M)5("NCC6['R)'?D#X?@+=QF%('*>6T/F$-'],[5'R$1';8@7*;BU9,/5$$3C)L8_"[5WM`ILB^8S3>0H?82/QM;+FCKN?3D\%2J#;2`PD4D-]189,K&R\V;O76UCMV8^^[""C2&HKT9L,C):9L-HK-J4'%B9`AMM8%.>MP,5FK,"FP2'^YQX;!GE`S_O,`2>.*I>)3M%-QHWW]P6:+C8?A=UPVXM1UOB2,$`=M"KA4!,E>B8U@;HA0&0XE4-4#XG:6U%1SYO!YU#PRM8P?0F+JC@XM4!.IV33EFIHYM_V!7^HV6_/`2FSTHV"VY7LAFG=U-@>UC-D'CKI";:UUH,T,M']\YC,W4A,]$+C-C"W^L>3(E#7ZW8B%ZCVT^S_AR[X]SC\FLT1>\AH;I3JCL,B?65%Q(AWU\I5T969W6:?9NVM1FV'Q,O,,I3YMTD#V#+WVLUA]PM;K6@?7O[LMK08$NQUOR#/N;CDB3[G,W8A0Y9"ZMY$&I6.:UB6P>C=>P&&PE%\-0L#!N3ZD61]C["S(N?I*!D+;,"V:R;F$!Q+K",WA/IP0E=ZFY"J:Z!1K>_MGH,/IYU2"TP+.!)DPIBHMEOIET40\XHVO=+S;,-T/F,$*;2&*Z^M1@)9J,.$M*MS.M&U"@VNO[1!9Y:H@E^Q)/U8X(NR9872[#QUV4D*NHR6[#!"FSO_28VX+MB_QZBS^V`O120V2$S+$Z^D1S)\(RH$F'R$Q>NS.Z").,)L/C3#SSE._"Y8^M\B??R#R+$.H>ZR_>ZU&1V2O_W3&59QM`=%2?3?13.Q6?@\9V7ASB-7/@-L5HM;!J_UR5?J#Z_",:F-TNB"F_7R6Q&XR@UKI$,>+MZ*6XP'DQ""IR"_XA0:0A-"!B(L(?#D9=00Q!8F9!-HM\`'[I1,(4NU*`#]Z#U0VM$`Q*CSTNP][>@@8?(G;@+!E#HA"QC13G+C->0A.O+1#\\N;_4B\/'NXD8B*\O^U#);D_Q:+`0.`LH?,(/$X(VS]+/3D$@M7X\3MHKV(-,0>P)4;J_SQD+D5M/F3B[A$/`WA7&[_*N?5.AEKH^-'BJ6M0DPN1:DLD^>`MK)40*R/BQC*(@])64[U\D(G(!?A"X_8V1S"FNP*JP!M$4;*]FD_(L)"2N0CN4,2-C#E!K#);+,B4M,TGRP$.0,'P:XB!H3,!/$FK4('M5P".Q=5A?#;1V3;E6LI:N$G^BP60&)F"8925V+'76JH5X'K.D0`6-#BVK24H).;-WFD52%AUYWY:M4=#ZJ+=&YLHS!?U';&2NE0?:4^W45LUHF*2#96]1:=SO'"MDF&4:+=VV)4)#99DAY*@4$A5>N5?G!,LN5>;=(Q@WG5E*=8+LT58G8Y5UHNUMWG79JNAKC.F,JHEA*W9)DHB\[B5!++&CD*@O7L.,4E8I98.HG4ZCM&WH3>G1.L;P%@N]F38%%Z&4=:M0VP5%XDE^`A(-9:4#I"IJJ32"%V+E8?-F)0*NG>N!9GX5[?(RDVX25BDQ55!M983"$9`;J#VUP2RK#TZE4G0LF'G3R'.AYWW=)=*E^EY]MM9CX_YV&YR&^Y4BZ3H0ER[3#PJ4G:4:+JE+K"-5]Y357U.:N\&5?U28?:D%&9MSAQ(57@?>:P_Q[4N56[:-V7W5ZB2MYTO]Y7725XK67&MR/F1M-A-QA:0,J>@6I?*(@8N*4B6NO;"9N9B11[E9TW59K[%I(Z-5H0%-M-DRGE?O!/R>0O@A>#P/%4).=V;*8@8L).*OJ)L==-^9[1KQ:XT2IJJA!X*'2[4VMJ14SOUT>C:SE=K/3MC2^7K_E62Q63;42L4H_$]^2']J9H)M28%SBC9"6XUM;MDIO5%67C6LZB&-A;(]ZA6-YHF%T1X5&B8`[>7V>6_^)0V2J1YMU?Y6B=J)/GMDL[-6UG=%!A/`W*#&'!5FEW#C3*1LO1QGO).@U2#K;1V;HZVYG%@E-+WVO?WMN1&T]=1Z?'NJ-GO\IB^BZ5TL6)[S%E@\F-4:DB@2IBPZB`WZ8TY8'H-S\F2AM3*'-6@`7DQ,48JDF4\!ED5(25*Y-("DH,>9"D0UG!YL2:Z4D1(I$-5X6:MN$18I%V[-%8,EO(@'#XX'C$-F1"A(Z-/*!;A86,JPF*GJCZ:F4:4I%A;';I4MP_'E$R>VYO"KA'`2JU)6XE[4RK#873I/8@J]TK'KM8=N9(9)LU2]53V+7T\+$6(.12ADEQY=WA$JYXFII''5=5UIY5'89LH)BXV_4RQQ:O>M6BQ>&5NG=,!8:YQ1W">"-?7\0A43/?IF6F3Z!%U3[Q?+7?*3:M]^5A)YZ)WDKGWJ%W7M6@@3][+"K(L"0.$"S%/"4*,F?/=%L)EH#(63DX%H"Z@BII5SSN:50SBWWW!GBI:M!8T]2HZ%$ZJT3@7JS_\I#Y2QI`YR(_C%2"C:H@V!4L99A:HAI?A('R35%NS)MW0X*D,D-C.,YY3Q!4`(G'\IBY=K5M2'>-_G,@MNA6'5@LF=':VO_>8(Q?/0QG]UN'Z-NO_%%M)GNCB=5&@Y-W+)WM.>]\:/8:'-!AYNE9"9[O4>.XL!!'>%HEJN^>3MN^W@[SMR/?\[1QO'-O.+MVPR2U$%YN1Q*6TY"DM'N]Z@WQM>B8SOHN^9D('NZPAKW@!SDJ`'#J9)%MDJJQAJE[^1M]]B'F^:$S-FC[&>@)(6:.[ANJXJ8_+6Q0\J1QFJOFY.>N$FRXM,NQE.B`_B3E`&XC('1A@&X>(;2ELD2(*U)(,'3J@2CM3&(A&(.&]8P>2"T/S(;%Y`:6!&WHZ.P0S$9[=`&'14J:.&TP*S/M'.W;ZHW;MD,1A"W;QA$4U`O_@Z#(UGIMC?0!X$HME+P+>\%9Z7A%WJX+`4SS,TNANJFQ[^JUR-,MB_T*1V8$R_3B*@S)AX4;0&=772W9(,$7@T/Z7M(!#PT@M\RO7M@L\!UDR!XS6_IJ4;.-T\`U.4N&MAHDOPR53O@B./#\VT+7+:M=Q@F"M+S,,OVR-/:>1H11-+#.H$7@&-W.MY4!OBD$O&M">NXN2.Z%%SW9:!Y&DV,Z08X(X,0RQ_L&4\ZH4-"F_F%VM3,PY\J1XL1MIL-V^CSOBNEQ[UT8R6Q]/F?V[-I],*,;#H&X'+1[]@U.!YI&4VB`]M:3$:BF%MM,EGK3&Q6H$%,?&3$FK@\N$\`.+4RQ3XL+.26$=$A9$9N.A$&';D]1.9*@UZMHZ,^YYBHG45:H?77-+Q%=J,K2HZQ3X`VL:A?/E%YZ-M!_RFB%\=\_V$F&WJ(MS**6$NNT2HH%`=D?+'\L1$=TX#`;XGISAV+434$+R1(X1(E9">3O.094UF*KN%@.ZO(R,J6PSU**7SU7>87/-2`N8HU]QVHGS3-M+`A0+"0N,Q)"`X4W68FO#"@C,U6F,E!U`EK49:)T"7FK37`!Z:27=4Y%T#1LMX,;?P!UR.IBIUBW6!@5>*-UF?SMZ*D84N@D20GZX]@2B%2AY4$:P\MZ!5LEL1QH^=X/`:7FYZ/7:06*8%:N>Z'IC`[32]LXMLKPQ)6"%B8!"W60-026G*#I[61:?!R&MELMUS$HG:Z2-=Q(P#2)0RU4SH10N,('=?DE13;K;V1T&R3SN*PW^;*7/[/?#IH]N]_,B-KJ'ABD.9E`*78UICF!,HYD!46]0%Y!`")HDMRN4\@O$%";%GI$IE2J"@5M-G4ZIUA\N62U:2?60S7#5Q#GMMIKM#SG=3LX0*ONK%(;41I>N30,"LD3#FL[E3\JP]H&GJ*--5JMIH'568W8>4H">6*:+73H_L(&V#ADRZ=G71_Z.K*H:M$2RROTDDDFL5DI59BF"@R&2A0C*[.$8)2Q'FL&IX`UJ9(F]Y([M3W,)Z',3H;JR8-R/,`L47;0D=#*K2[LK3^NS%^D)H8@40W$Q]@*7H\HTI?JQMH\L9:[&N%]DN]HF?\Z`[)KE:U3AZ83M-B@D(8E@Z`(OP8)@-`I,M@SV!8J;!6X*NB"#NY*8+GJZ@6O#HW&0J0^+-MM/+NM(11L*DP#?:&\/].#G(XEN,NB4CJOPYX!D3`/H3%$>HJ8()6.Z*`4MJJL+^RM>\#\M,\?@VS$Q8;TP5!PJ`R=43#ZS_!27R2&>V(A'$B/>(\#ALZ:PMB"''M#"2(1-_,+>H7)N@@8+5"`:P$K)1`)D1A8YC0;!T7+W_+&`/6]I"4ZFMMQQR\=&N%D_#$ULRJ"CTX,S1(::L61`PF9G*]:N*WI9D\8H(4]9&>B@*AKK(]MIJ!+.3FSZFL5,CW"1AK!/7O"F=')_#&;I;1`_@JM99I+&IN544!`8")*KC"FM:R/2*_N9/%NV9@,Y5\N;G8&@$S49V@-`:&.D6XPP2W,_JY0A*6"/8V(FPWO#M)\DK_M.V$%499ME!"'',MQ(61WW3=ONK*!4'!JJ6)LS"UR..FS!47FA-`F2[3X1526#GZ0T9VC+^OM.IXI;4>[ZRA;BB2*TSUWG!57X%P[H1;PH=^>2*2'H3M0NS,D:31+RP>"948%M^:G9;)SK[)JM!#;6N2D[!0RA@S9U!#!HK9ON@DN=E6F"6.:HM+VVRREB+SZ]:E("DP1I'S-M0'"572FXM5$XI8%;,6$]+5RCYS;_AT")\*"7AJF1".R(1O&I5&N$DW!SVEQ4T,Y:B'Z>UM$)U+VY,^&H-+"?]7X,_D6DUT>@E&_=NHO$G11%W]0];!BH[U#">-Z%IUEC76MP-8_4T)=61T\:CQ[24I.\`2N8`3.^**HA)Y_,=Q)+`2BMA&[:R5D"!S."!FLMQHMH,EC1`#:#O8))X`2O6)/U/J(*$6J=-HV;;J@BJ1J#K>D&$-R"R.^^_(U@M21C?'MWI(PL38,M/U+T9=D*VO:P*?W)P@*5(M.46!HYULF)M;2G%#1V^]^Z_!XF,O-#L;*T6#R!.MS&Q2.U92AR13^(8PBA%1+B/>9=5P90-D&,&^'*D["S,:4$WRQJ8SRF@=:K#%NF155LPS?.8C.$RMD*1?5D.;CDSHG`]FIN6M2[H!_2`24`(2:0QH)F$R-@8ZK@U.NN,]U@*RV"L:FN9JCK/.4($0"NI#_4-))B4T'F>*YV>M:W/`\/(2BXF"#`0JH+"\0>HU]HG&(X(2T?!$)HK#&AL/#`\Q4X\8VC,EK#\J8:,1VQX5\2Z#:_S_6"TPPSM@9S+AED+1ZJ_X0UA8,^'$O$O/[PZDQ2M$*%R%+A`]LXQR8BM()HN6*=CZS(KA=0QDFS:@-1B)"/(@A/0*^8Y_\50=],EAG?["6YT['-+?.9KEZX@@ZVM!)UK#'3+-GE#`B*QQV-QTCMRV\!,G:5$FWV>BD?^)"X$3$W17$MN]O5A@9+#P7)31L`O9O5A:T-BD>NA`BUMW7+X6@06*^O:BZP=7TUY5'$$26"ITFN4TS4[M'3`0,^P38,8,`E/HHIS/_T;4A'#)>+F!ET(\K(2V@A4_Y%'1PP>M)M(G,#\.CXO)++\CL!+QJO`\2/@AS]ON3GSY*[4KKO6I_@07\@DGYU2F.>95MZ71RB,E!8(19!Y*D)IB3[-#>8@H+N7T3P*7/QK1735M12Y`SSEKWS4_^2,B'MC'`4C"[)"`QA`MU5W-K8P2?Z%%5"`72[6-"P3**YW"+#\629(@F_99MMYR42_B@]>_&2FV:*8W5X#V(F@^9YB(9'-XEE8B=[*W$9R#(QANJ1S;`4/E&_-M+ZI^S:A(TPC-PX;\&6+%M+[$BDX)RBM`+%Y@9/(&GK(2>-N/-9],%GNIW'O,N^=CC#AEV93Z6@@SDB6"!M_(H!^\22"U)9["8L9\B5H:W'4#!XI^E2ZM*M*QEY"-QSBC9.(Y;/I\C/SBVNY*!*;8JFXE(8_08OLK1QE\QV`IE!=)9IMX_P0Q*MD($J&E%3!+&?HL9FC0/V+6;C:-)#Q?G?23"5,?ZI276@>5`V>J6YC:"&)MUJM"F/I?Y$*"9)?(HTQS\,R8M`-9RQ,0!N:!3/Q]_]V5/M1&(E!47LKPM)GE*%M!3)A_OW4%BM9V$86T85;/70B:'2>NAC-5-R4$Y69-0'91I1>.,G;8CWAUD65B,#:H*P>M9PM8N-S=5G%99_6@JJC'+5A%\8%)>]G:W&Q,QDBB5]7*/,$>MVT_VMX0G(BYE`7M!PF,=H;X$`Z2AB>=0V>:^`[`-VDR"&?7AC5A18J&E#:=%FV&6!R-$RX]>'S^M5E8Q=78(`XK>)(^0F(2"%PO*&"\7$8YC1R=WP5/'@W%K`EY60S+Z@'`D07U^ME(`6\E?/,-(QF3V7-Z.2"`M*X$C>*F!S`6#VS@?^3..G?1V?40R9KJH6Q]5:MK0BDN9-$9G=9R1M>K*0AK[$&[\H)>FT4=$H:74X3^V$-JM9"(6Y-4&A36\R2$4:+T@*HQST@Z8)M@A3IBCRB)'9X#J!7G3?F70>BC04E#G-$9+:@%"4GMF)61@DL5(NM9Q"\*9N315/JN1^SI81/]FTVY8J!EX\&18ZZZB=CM!RGDZ@,1*U0%T9?'QXA'.&_'Y72^P*XKFPJ\^G0[+MF(#-AG#.-BI#RZ14NHV]%;#RJ+.NA29"ZUUB\WY?R"BN[]'.(=]9U>